Arvinas, Inc. (ARVN)Healthcare | Biotechnology | New Haven, United States | NasdaqGS
8.10 USD
-0.17
(-2.056%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:06 a.m. EDT
The investment case for Arvinas is currently fractured by a severe disconnect between its operational reality and its market valuation. Fundamentally, the company is in distress: revenue has collapsed by nearly 92% year-over-year, profitability is nonexistent, and the stock has erased roughly 69% of its value over the last six years. This multi-year decline is not a temporary dip but a structural deterioration confirmed by the market, leaving the stock with no safety margin despite its low price-to-book ratio. The recent catalyst of a new CEO and FDA approval for a breast cancer drug has sparked retail optimism, yet the data suggests this is insufficient to reverse the trend immediately. The company is burning significant cash with no path to profitability visible in the near term, and the balance sheet, while currently liquid, cannot sustain indefinite losses without dilution or capital raises. Short-term, the sentiment remains fragile. Options data reveals a defensive posture with heavy put buying, indicating that even traders who believe in the long-term potential are hedging against further declines. The statistical forecast models also lean slightly negative, aligning with the broader technical weakness. While the new leadership team offers hope for a turnaround, the current fundamentals—specifically the massive revenue contraction and lack of earnings—make this a high-risk speculative play rather than a viable investment. Until revenue growth stabilizes and the burn rate is addressed, the risk of further capital destruction outweighs the potential for a quick rebound. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.098443 |
| AutoARIMA | 0.180462 |
| AutoETS | 0.180462 |
| MSTL | 0.185475 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 5.98 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.425 |
| Excess Kurtosis | -0.64 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.172 |
| Revenue per Share | 1.3 |
| Market Cap | 522,621,760 |
| Forward P/E | -2.35 |
| Beta | 1.75 |
| Profit Margins | -247.54% |
| Website | https://www.arvinas.com |
As of July 11, 2026, 3:06 a.m. EDT: Speculators are positioning defensively with heavy put volume relative to calls, particularly in the near term where out-of-the-money puts dominate open interest. While there is some call activity at strikes significantly above the current price (indicating a speculative long tail), the overwhelming weight of open interest sits in protective puts, suggesting a consensus expectation of further downside or volatility rather than a breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.050825953 |
| Address1 | 5 Science Park |
| Address2 | 395 Winchester Avenue |
| All Time High | 108.47 |
| All Time Low | 5.9 |
| Ask | 10.25 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Daily Volume10 Day | 894,800 |
| Average Daily Volume3 Month | 837,536 |
| Average Volume | 837,536 |
| Average Volume10Days | 894,800 |
| Beta | 1.749 |
| Bid | 5.88 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 5.997 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.1 |
| Current Ratio | 5.442 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 8.24 |
| Day Low | 7.945 |
| Debt To Equity | 2.172 |
| Display Name | Arvinas |
| Earnings Call Timestamp End | 1,778,587,200 |
| Earnings Call Timestamp Start | 1,778,587,200 |
| Earnings Timestamp | 1,778,589,000 |
| Earnings Timestamp End | 1,785,933,000 |
| Earnings Timestamp Start | 1,785,933,000 |
| Ebitda | -246,500,000 |
| Ebitda Margins | -2.7572699 |
| Enterprise To Ebitda | 0.34 |
| Enterprise To Revenue | -0.938 |
| Enterprise Value | -83,878,296 |
| Eps Current Year | -2.86389 |
| Eps Forward | -3.44922 |
| Eps Trailing Twelve Months | -3.18 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.625 |
| Fifty Day Average Change | -0.5249996 |
| Fifty Day Average Change Percent | -0.060869522 |
| Fifty Two Week Change Percent | 5.0825953 |
| Fifty Two Week High | 14.51 |
| Fifty Two Week High Change | -6.41 |
| Fifty Two Week High Change Percent | -0.4417643 |
| Fifty Two Week Low | 6.06 |
| Fifty Two Week Low Change | 2.0400004 |
| Fifty Two Week Low Change Percent | 0.33663374 |
| Fifty Two Week Range | 6.06 - 14.51 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,538,055,000,000 |
| Float Shares | 55,804,384 |
| Forward Eps | -3.44922 |
| Forward P E | -2.3483572 |
| Free Cashflow | -199,637,504 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 246 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 1.34452 |
| Gross Profits | 120,200,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07907 |
| Held Percent Institutions | 0.82835 |
| Implied Shares Outstanding | 64,521,198 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut. |
| Long Name | Arvinas, Inc. |
| Market | us_market |
| Market Cap | 522,621,760 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_243040896 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -221,300,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 533,590,307 |
| Number Of Analyst Opinions | 15 |
| Open | 8.24 |
| Operating Cashflow | -254,100,000 |
| Operating Margins | -4.05128 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 203 535 1456 |
| Pre Market Change | -0.06000042 |
| Pre Market Change Percent | -0.7407459 |
| Pre Market Price | 8.04 |
| Pre Market Time | 1,784,016,768 |
| Previous Close | 8.27 |
| Price Eps Current Year | -2.8283212 |
| Price Hint | 2 |
| Price To Book | 1.3506753 |
| Price To Sales Trailing12 Months | 5.845881 |
| Profit Margins | -2.47539 |
| Quick Ratio | 5.361 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.17 |
| Regular Market Change Percent | -2.05562 |
| Regular Market Day High | 8.24 |
| Regular Market Day Low | 7.945 |
| Regular Market Day Range | 7.945 - 8.24 |
| Regular Market Open | 8.24 |
| Regular Market Previous Close | 8.27 |
| Regular Market Price | 8.1 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 654,915 |
| Return On Assets | -0.18917999 |
| Return On Equity | -0.42277 |
| Revenue Growth | -0.917 |
| Revenue Per Share | 1.3 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 64,521,198 |
| Shares Percent Shares Out | 0.066199996 |
| Shares Short | 4,268,156 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,706,811 |
| Short Name | Arvinas, Inc. |
| Short Percent Of Float | 0.0773 |
| Short Ratio | 4.91 |
| Source Interval | 15 |
| State | CT |
| Symbol | ARVN |
| Target High Price | 24.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 14.8 |
| Target Median Price | 15.0 |
| Total Cash | 614,899,968 |
| Total Cash Per Share | 9.53 |
| Total Debt | 8,400,000 |
| Total Revenue | 89,400,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.18 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.69845 |
| Two Hundred Day Average Change | -2.5984497 |
| Two Hundred Day Average Change Percent | -0.24288096 |
| Type Disp | Equity |
| Volume | 654,915 |
| Website | https://www.arvinas.com |
| Zip | 6,511 |